hCAR-EGFP fusion receptor in human follicular lymphoma B cells - A model for adenoviral gene therapy for B cell malignancies

International Journal of Molecular Medicine

Volumn 17, Issue 6, 2006, Pages 1057-1062

  Mättö, Mikko ^a   Nuutinen, Ulla Maija ^a   Hakkarainen, Tanja ^a,d,e   Tallone, Tiziano ^b   Wahlfors, Jarmo ^a   Pelkonen, Jukka ^a,c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b POLYGENE AG   (Switzerland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

B cell and human; EGFP; Fusion gene; hCAR; Lentiviral vectors; Transduction

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; HCAR EGFP FUSION RECEPTOR; HCAR-EGFP FUSION RECEPTOR; HYBRID PROTEIN; PHOTOPROTEIN; THYMIDINE KINASE; VIRUS RECEPTOR;

ADENOVIRUS; ARTICLE; B CELL LYMPHOMA; DRUG RESISTANCE; FOLLICULAR LYMPHOMA; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HUMAN; TUMOR CELL LINE;

ADENOVIRIDAE; ANTIVIRAL AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; HUMANS; LUMINESCENT PROTEINS; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; RECEPTORS, VIRUS; RECOMBINANT FUSION PROTEINS; THYMIDINE KINASE; TRANSDUCTION, GENETIC;

EID: 33745727520     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.17.6.1057     Document Type: Article

References (36)

1. Hoelzer D, Gokbuget N, Ottmann O, Pui CH, Relling MV, Appelbaum FR, van Dongen JJ and Szczepanski T: Acute lymphoblastic leukemia. Hematology pp162-192, 2002.
2. Pui CH, Schrappe M, Ribeiro RC and Niemeyer CM: Childhood and adolescent lymphoid and myeloid leukemia. Hematology pp118-145, 2004.
3. Diehl V, Stein H, Hummel M, Zollinger R and Connors JM: Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology pp225-247, 2003.
4. Fisher RI, Miller TP and O'Connor OA: Diffuse aggressive lymphoma. Hematology pp221-236, 2004.
5. Cantwell MJ, Sharma S, Friedmann T and Kipps TJ: Adenovirus vector infection of chronic lymphocytic leukemia B cells. Blood 88: 4676-4683, 1996. (Pubitemid 26419152)
6. Von Seggern DJ, Huang S, Fleck SK, Stevenson SC and Nemerow GR: Adenovirus vector pseudotyping in fiber-expressing cell lines: improved transduction of Epstein-Barr virus-transformed B cells. J Virol 74: 354-362, 2000.
7. White RE, Wade-Martins R and James MR: Infectious delivery of 120-kilobase genomic DNA by an epstein-barr virus amplicon vector. Mol Ther 5: 427-435, 2002.
8. Hellebrand E, Mautner J, Reisbach G, Nimmerjahn F, Hallek M, Mocikat R and Hammerschmidt W: Epstein-Barr virus vector-mediated gene transfer into human B cells: potential for antitumor vaccination. Gene Ther 13: 150-162, 2006. (Pubitemid 43039907)
9. Wendtner CM, Kofler DM, Theiss HD, Kurzeder C, Buhmann R, Schweighofer C, Perabo L, Danhauser-Riedl S, Baumert J, Hiddemann W, Hallek M and Buning H: Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors. Blood 100: 1655-1661, 2002.
10. Bovia F, Salmon P, Matthes T, Kvell K, Werner-Favre C, Nguyen TH, Barnet M, Nagy M, Leuba F, Arrighi JF, Piguet V, Trono D and Zubler RH: Efficient transduction of primary human B lymphocytes and nondividing myeloma B cells with HIV-1-derived lentiviral vectors. Blood 101: 1727-1733, 2003. (Pubitemid 36237567)
11. Quartier P, Debre M, De Blic J, De Sauverzac R, Sayegh N, Jabado N, Haddad E, Blanche S, Casanova JL, LeDeist F, Smith CI, De Saint Basile G and Fischer A: Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr 134: 589-596, 1999.
12. Kovesdi I, Brough DE, Bruder JT and Wickham TJ: Adenoviral vectors for gene transfer. Curr Opin Biotechnol 8: 583-589, 1997.
13. Koizumi N, Mizuguchi H, Sakurai F, Yamaguchi T, Watanabe Y and Hayakawa T: Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation. J Virol 77: 13062-13072, 2003.
14. Anonymous Assessment of Adenoviral Vector Safety and Toxicity: Report of the National Institutes of Health Recombinant DNA Advisory Committee. Hum Gene Ther 13: 3-13, 2002.
15. Hakkarainen T, Hemminki A, Pereboev AV, Barker SD, Asiedu CK, Strong TV, Kanerva A, Wahlfors J and Curiel DT: CD40 is expressed on ovarian cancer cells and can be utilized for targeting adenoviruses. Clin Cancer Res 9: 619-624, 2003. (Pubitemid 36182593)
16. Pereboev AV, Asiedu CK, Kawakami Y, Dong SS, Blackwell JL, Kashentseva EA, Triozzi PL, Aldrich WA, Thomas JM, Curiel DT and Dmitriev IP: Coxsackievirus-adenovirus receptor genetically fused to anti-human CD40 scFv enhances adenoviral transduction of dendritic cells. Gene Ther 9: 1189-1193, 2002.
17. Colin M, Renaut L, Mailly L and D'Halluin JC: Factors involved in the sensitivity of different hematopoietic cell lines to infection by subgroup C adenovirus: implication for gene therapy of human lymphocytic malignancies. Virology 320: 23-39, 2004.
18. Siemasko K and Clark MR: The control and facilitation of MHC class II antigen processing by the BCR. Curr Opin Immunol 13: 32-36, 2001.
19. Pellinen R, Hakkarainen T, Wahlfors T, Tulimaki K, Ketola A, Tenhunen A, Salonen T and Wahlfors J: Cancer cells as targets for lentivirus-mediated gene transfer and gene therapy. Int J Oncol 25: 1753-1762, 2004.
20. Matto M, Nuutinen UM, Ropponen A, Myllykangas K and Pelkonen J: CD45RA and RO isoforms have distinct effects on cytokine- and B-cell-receptor-mediated signalling in human B cells. Scand J Immunol 61: 520-528, 2005. (Pubitemid 40897107)
21. Hsu KH, Lonberg-Holm K, Alstein B and Crowell RL: A monoclonal antibody specific for the cellular receptor for the group B coxsackieviruses. J Virol 62: 1647-1652, 1988.
22. Wieland S, Dobbeling U and Rusconi S: Interference and synergism of glucocorticoid receptor and octamer factors. EMBO J 10: 2513-2521, 1991.
23. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM and Trono D: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263-267, 1996.
24. Hakkarainen T, Wahlfors T, Merilainen O, Loimas S, Hemminki A and Wahlfors J: VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22-HSVTk-GFP triple fusion construct. J Gene Med 7: 898-907, 2005.
25. Eray M, Postila V, Eeva J, Ripatti A, Karjalainen-Lindsberg ML, Knuutila S, Andersson LC and Pelkonen J: Follicular lymphoma cell lines, an in vitro model for antigenic selection and cytokine-mediated growth regulation of germinal centre B cells. Scand J Immunol 57: 545-555, 2003.
26. Palu G, Cavaggioni A, Calvi P, Franchin E, Pizzato M, Boschetto R, Parolin C, Chilosi M, Ferrini S, Zanusso A and Colombo F: Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. Gene Ther 6: 330-337, 1999. (Pubitemid 29132336)
27. Bouaboula M, Legoux P, Pessegue B, Delpech B, Dumont X, Piechaczyk M, Casellas P and Shire D: Standardization of mRNA titration using a polymerase chain reaction method involving co-amplification with a multispecific internal control. J Biol Chem 267: 21830-21838, 1992.
28. Wierda WG and Kipps TJ: Gene therapy of hematologic malignancies. Semin Oncol 27: 502-511, 2000.
29. Li L, Wickham TJ and Keegan AD: Efficient transduction of murine B lymphocytes and B lymphoma lines by modified adeno-viral vectors: enhancement via targeting to FcR and heparan-containing proteins. Gene Ther 8: 938-945, 2001.
30. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, LeDeist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M and Fischer A: A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348: 255-256, 2003.
31. Thomas CE, Ehrhardt A and Kay MA: Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4: 346-358, 2003.
32. Tomko RP, Xu R and Philipson L: HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 94: 3352-3356, 1997. (Pubitemid 27157315)
33. Rebel VI, Hartnett S, Denham J, Chan M, Finberg R and Sieff CA: Maturation and lineage-specific expression of the coxsackie and adenovirus receptor in hematopoietic cells. Stem Cells 18: 176-182, 2000. (Pubitemid 30341665)
34. Richards JL, Abend JR, Miller ML, Chakraborty-Sett S, Dewhurst S and Whetter LE: A peptide containing a novel FPGN CD40-binding sequence enhances adenoviral infection of murine and human dendritic cells. Eur J Biochem 270: 2287-2294, 2003. (Pubitemid 36605578)
35. Pettersson S, Cook GP, Bruggemann M, Williams GT and Neuberger MS: A second B cell-specific enhancer 3′ of the immunoglobulin heavy-chain locus. Nature 344: 165-168, 1990.
36. Takahashi S, Yotnda P, Rousseau RF, Mei Z, Smith S, Rill D, Younes A and Brenner MK: Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma. Cancer Gene Ther 8: 378-387, 2001. (Pubitemid 32685645)